Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 366

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Open access
Ma, Cynthia X., Gao, Feng, Luo, Jingqin, Northfelt, Donald W., Goetz, Matthew, Forero, Andres, Hoog, Jeremy, Naughton, Michael, Ademuyiwa, Foluso, Suresh, Rama, Anderson, Karen S., Margenthaler, Julie, Aft, Rebecca, Hobday, Timothy, Moynihan, Timothy, Gillanders, William, Cyr, Amy, Eberlein, Timothy J., Hieken, Tina, Krontiras, Helen, Guo, Zhanfang, Lee, Michelle V., Spies, Nicholas C., Skidmore, Zachary L., Griffith, Obi L., Griffith, Malachi, Thomas, Shana, Bumb, Caroline, Vij, Kiran, Bartlett, Cynthia Huang, Koehler, Maria, Al-Kateb, Hussam, Sanati, Souzan, Ellis, Matthew J.·2017·Clinical Cancer Research

Abstract

Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− breast cancer received anastrozole 1 mg daily for 4 weeks (cycle 0; with goserelin if premenopausal), followed by adding palbociclib (125 mg daily on days 1–21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67 > 10%, in which case patients went off study due to inadequate response. Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. Serial biopsies at baseline, C1D1, C1D15, and surgery were analyzed for Ki67, gene expression, and mutation profiles. The primary endpoint was complete cell cycle arrest (CCCA: central Ki67 ≤ 2.7%). Results: Fifty patients enrolled. The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P < 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. B) and PIK3CA status with activity observed across a broad range of clinicopathologic and mutation profiles. Ki67 recovery at surgery following palbociclib washout was suppressed by cycle 5 palbociclib. Resistance was associated with nonluminal subtypes and persistent E2F-target gene expression. Conclusions: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect. Clin Cancer Res; 23(15); 4055–65. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-3206

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 366

Metadata

Authors
Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T., Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., Krontiras, H., Guo, Z., Lee, M. V., Spies, N. C., Skidmore, Z. L., Griffith, O. L., Griffith, M., Thomas, S., Bumb, C., Vij, K., Bartlett, C. H., Koehler, M., Al-Kateb, H., Sanati, S., & Ellis, M. J.
Venue
Clinical Cancer Research
Published
2017-08-01
Volume
23
Issue
15
Pages
4055-4065
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2592406193
Cited by
366
References
48
FWCI
26.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3206
The paper
Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T., Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., . . . Ellis, M. J. (2017). NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3206

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.